Head-To-Head Survey: NeuroDerm (NDRM) vs. The Competition
NeuroDerm (NASDAQ: NDRM) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare NeuroDerm to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.
Risk & Volatility
NeuroDerm has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, NeuroDerm’s competitors have a beta of 6.57, indicating that their average stock price is 557% more volatile than the S&P 500.
This table compares NeuroDerm and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for NeuroDerm and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NeuroDerm presently has a consensus target price of $45.86, suggesting a potential upside of 17.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.51%. Given NeuroDerm’s competitors stronger consensus rating and higher possible upside, analysts clearly believe NeuroDerm has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
52.4% of NeuroDerm shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares NeuroDerm and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|NeuroDerm Competitors||$473.33 million||$171.77 million||-6.98|
NeuroDerm’s competitors have higher revenue and earnings than NeuroDerm. NeuroDerm is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
NeuroDerm competitors beat NeuroDerm on 8 of the 12 factors compared.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson’s disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.
Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.